Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant b cells and on a human/mouse model of burkitt lymphoma

Current Clinical Pharmacology

Volumn 5, Issue 4, 2010, Pages 246-250

  Marín, Gustavo H ^a   Mansilla, Eduardo ^a   Mezzaroba, Nelly ^b   Zorzet, Sonia ^b   Núñez, Luis ^c,d   Larsen, Gustavo ^d,e   Tau, José M ^a   Maceira, Alberto ^a   Spret, Ruben ^d,e   Mertz, Carol ^f   Ingrao, Sabrina ^g   Tripodo, Claudio ^g   Tedesco, Francesco ^b   Macor, Paolo ^b  

^a CUCAIBA   (Argentina)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF CHICAGO   (United States)

^d Bio Target   (United States)

^e LNKChemsolutions   (United States)

^f ARGONNE NATIONAL LABORATORY   (United States)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

B cells; Chlorambucil; CLL; Hydroxychloroquine; Lymphoma; Nanoparticles; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORAMBUCIL; HYDROXYCHLOROQUINE; MONOCLONAL ANTIBODY; NANOPARTICLE; RITUXIMAB;

ANIMAL; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; C57BL MOUSE; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL SURVIVAL; CHLORAMBUCIL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; HYDROXYCHLOROQUINE; MICE; MICE, INBRED C57BL; NANOPARTICLES; TUMOR CELLS, CULTURED;

EID: 79952276335     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410793352058     Document Type: Article

References (21)

1. Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H. Longterm follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. Eur J Haematol 2000; 65(1): 17-22.
2. Piccaluga PP, Martinelli G, Baccarani M. Advances in the treatment for haematological malignancies. Expert Opin Pharmacother 2006; 7(6): 721-32.
3. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. J Med Invest 2003; 50(3-4): 126-35.
4. Jønsson V, Gemmell CG, Wiik A. Emerging concepts in the management of the malignant haematological disorders. Expert Opin Pharmacother 2000; 1(4): 713-35.
5. Sinico C, Fadda AM. Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv 2009; 6(8): 813-25.
6. Islam T, Josephson L.Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomarkers 2009; 5(2): 99-107.
7. Rao DA, Forrest ML, Alani AW, Kwon GS, Robinson JR. Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci 2010; 99(4): 2018-31.
8. Luo G, Yu X, Jin C, Yang F, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm 2010; 385(1-2): 150-6.
9. Arias JL, Reddy LH, Couvreur P. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J Drug Target 2009; 17(8): 586-98.
10. Matsumura Y. Polymeric micellar delivery systems in oncology. Jpn J Clin Oncol 2008; 38(12): 793-802.
11. Enbäck J, Laakkonen P. Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 2007; 35(Pt 4): 780-3.
12. Mansilla E, Marin GH, Nuñez L et al. The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm 2010; 25(1): 97-103.
13. Turturro F. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival. Expert Rev Anticancer Ther 2007; 7(7): 959-65.
14. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007; 67(21): 10556-63.
15. Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004; 83(10): 634-45.
16. Biffi S, Garrovo C, Macor P, et al. In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. Mol Imaging 2008; 7(6): 272-82.
17. Assayag F, Brousse N, Couturier J, et al. Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab. J Hematol 2009; 84(6): 387-8.
18. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl- 2/bax/ratio. Leuk Lymphoma 2002; 43(5): 1087-95.
19. Dighiero, G., Maloum, K., Desablens B. Chlorambucil in Indolent Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506-14.
20. Rai, K. R., Peterson, B. L., Appelbaum, F. R. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343:1750-8.
21. Huhn, D., von Schilling, C., Wilhelm, M. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 5: 1326-31.